Erratum: Type 1 regulatory T cell-mediated tolerance in health and disease

Frontiers Production Office

doi:10.3389/fimmu.2022.1125497

. 2023 Jan 24;13:1125497. doi: 10.3389/fimmu.2022.1125497

Erratum: Type 1 regulatory T cell-mediated tolerance in health and disease

Frontiers Production Office^1,^*

PMCID: PMC9903213 PMID: 36761160

Due to a production error, there was a mistake in Table 1 as published. Some of the citations in Table 1 did not link to the correct references in the reference list. The corrected Table 1 appears below. The publisher apologizes for this mistake.

Table 1.

Overview of the role of Tr1 and IL-10-producing CD4⁺ T cells in AIDs and IBD.

Disease	Cell identity	Model	Major finding	Reference
*T1D*	FOXP3^- IL-10-producing CD4⁺ T cells	NOD BDC2.5 TCR-transgenic and NOD/SCID mice	Intestinal FOXP3^- IL-10-producing CD4⁺ T cells can protect from T1D	76
	IL-10-producing CD4⁺ T cells	NOD and NOD/SCID mice	Combination of rapamycin and IL-10 reduces incidence of diabetes	77
	GAD65-specific IL-10-producing CD4⁺ T cells	GAD65-immunized NOD and NOD/SCID mice	Protection from T1D in adoptive transfer experiments	78
	Antigen-specific IL-10-producing CD4⁺ T cells	Immunized NOD and NOD/SCID mice	Antigen-containing PLG nanoparticles protect from T1D	79
	CD49b⁺LAG-3⁺ Tr1 cells	Immunized NOD and NOD/SCID mice	IGRP- and 2.5mi/IA^g7 nanoparticles expand pre-existing Tr1 cells and protect from T1D	80
	Islet-specific IL-10-producing CD4⁺ T cells	Patient PBMCs	Higher frequency in healthy donors	81
	Islet-specific IL-10-producing CD4⁺ T cells	Patient PBMCs	Higher frequency in first degree relatives	82
	Insulin-specific IL-10-producing CD4⁺ T cells	Patient PBMCs	Higher in patients that have better future glucose control	83
	IGFR-specific IL-10-producing CD4⁺ T cells	Patient PBMCs	Higher frequency in juvenile T1D compared to adult T1D	84
	IL-10-producing CD4⁺ T cells	Patient PBMCs	Increase in IL-10-producing CD4⁺ T cells upon anti-CD3 treatment	85
	Proinsulin-specific IL-10-producing CD4⁺ T cells	Proinsulin-immunized patient PBMCs	Increase in IL-10 production and decrease in insulin dependency	86
	IGRP-specific CD49b⁺LAG-3⁺ Tr1 cells	IGRP-immunized NSG mice reconstituted with DR4 patient PBMCs	Induction of IGRP-specific CD49b⁺LAG-3⁺ Tr1 cells	80
MS	OVA-specific IL-10-producing CD4⁺ T cells	OVA-immunized MSCH-induced EAE mice	OVA-specific protection from EAE development	87
	IL-10-producing CD4⁺ T cells	MOG-induced EAE mice	IL27-pulsed DCs upregulate IL-10 production by CD4⁺ T cells for protection from EAE development	88
	CD49b⁺LAG-3⁺ Tr1 cells	MOG-induced EAE mice	Protection from EAE development independently of IL-10	89
	IL-10-producing CD4⁺ T cells	MOG-induced EAE mice	Melatonin induces IL-10-producing CD4⁺ T cells to protect from EAE development	65
	CD49b⁺LAG-3⁺ Tr1 cells	PLP-induced EAE mice	PLP- and MOG-containing pMHCII nanoparticles protect from EAE development	80
	IL-10-producing CD4⁺ T cells	PLP- and MOG-induced EAE	MOG- and AhR-containing NLPs protects from EAE development	90
	CD46-induced IL-10-producing CD4⁺ T cells	Patient PBMCs	Lower frequency in MS patients	91
	CD46-induced IL-10-producing CD4⁺ T cells	Patient PBMCs	Altered glycosylation of CD46 in MS patients	57
*SLE*	CD46-induced IL-10-producing CD4⁺ T cells	Patient PBMCs	Lower frequency in SLE patients	24
	IL-10-producing IL7R^- CD4⁺ T cells	Patient PBMCs	Decreased ability in limiting autoantibody production by B cells	16
	IL-10-producing CXCR5^-CXCR3⁺PD-1^high CD4⁺ T cells	Patient PBMCs	CXCR5^-CXCR3⁺PD-1^high CD4⁺ T cell-derived IL-10 can stimulate autoantibody production	92
*Arthritis*	Collagen type II-specific IL-10-producing CD4⁺ T cells	Collagen type II-immunized DBA/1 mice	Protection from arthritis development	93
*Psoriasis*	CD49b⁺LAG-3⁺ Tr1 cells	Patient PBMCs and skin biopsies	Presence of Tr1 cells inversely correlated with disease severity	94
*Celiac disease*	Gliadin-specific IL-10-producing CD4⁺ T cells	Patient intestinal T cells	Gliadin-specific suppression of effector T cells	44
	Gliadin-specific IL-10-producing CD4⁺ T cells	Patient PBMCs and intestinal T cells	Multi-epitope gliadin extract induces tolerance in celiac disease patients	95
*IBD*	OVA-specific IL-10-producing CD4⁺ T cells	CD4⁺CD45RB^high adoptive transfer mice	Prevention of colitis in recipient mice	4
	IL10-deficient CD4⁺CD45RB^low T cells	CD4⁺CD45RB^high adoptive transfer mice	Protection from colitis is dependent on IL-10	96
	IL-10-producing CD4⁺ T cells	CD4⁺CD45RB^high adoptive transfer mice	Prevention of Th17-mediated colitis	97
	IL-10-producing CD4⁺ T cells	DSS-induced colitis mouse model	GSK-J4-mediated induction of tolerogenic DCs to promote IL-10 production by CD4⁺ T cells	98
	IL-10-producing CD44⁺CD4⁺ T cells	TNBS-induced colitis mouse model	MSCs induce expansion of IL-10-producing CD44⁺CD4⁺ T cells	99
	Intestinal IL7R^-CCR5⁺PD-1⁺ Tr1 cells	Patient intestinal T cells	Decreased IL-10 production	30
	IL-10-producing OVA-Treg	Patient PBMCs	Amelioration of disease in treated patients	100
	CD49b⁺LAG-3⁺ Tr1 cells	Patient PBMCs and colon biopsies	Decrease of myeloid-derived inflammatory cytokines and production of IL-22 and mucin to promote barrier integrity	69

Open in a new tab

The original version of this article has been updated.

References

1. Bluestone JA, Anderson M. Tolerance in the age of immunotherapy. New Engl J Med (2020) 383:1156–66. doi: 10.1056/nejmra1911109 [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Roncarolo MG, Yssel H, Touraine J-L, Bacchetta R, Gebuhrer L, de Vries JE, et al. Antigen recognition by MHC-incompatible cells of a human mismatched chimera. J Exp Med (1988) 168:2139–51. doi: 10.1084/jem.168.6.2139 [DOI] [PMC free article] [PubMed] [Google Scholar]
3. Bacchetta R, Bigler M, Touraine J-L, Parkman R, Tovo P-A, Abrams J, et al. High levels of interleukin 10 production In vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med (1994) 179:493–502. doi: 10.1084/jem.179.2.493 [DOI] [PMC free article] [PubMed] [Google Scholar]
4. Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 389:737–42. doi: 10.1038/39614 [DOI] [PubMed] [Google Scholar]
5. Bacchetta R, Sartirana C, Levings MK, Bordignon C, Narula S, Roncarolo MG. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol (2002) 32:2237–45. doi: 10.1002/1521-4141(200208)32:8<2237::AID-IMMU2237>3.0.CO;2-2 [DOI] [PubMed] [Google Scholar]
6. de Waal-Malefyt R, Haanen J, Spits H, Roncarolo M-G, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med (1991) 174:915–24. doi: 10.1084/jem.174.4.915 [DOI] [PMC free article] [PubMed] [Google Scholar]
7. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol (1993) 151:1224–34. [PubMed] [Google Scholar]
8. Willems F, Marchant A, Delville J-P, Gerard C, Delvaux A, Velu T, et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocyt es. Eur J Immunol (1994) 24:1007–9. doi: 10.1002/eji.1830240435 [DOI] [PubMed] [Google Scholar]
9. Chang C-H, Furue M, Tamaki K. B7-1 expression of langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-y or by int erleukin-10. Eur J Immunol (1995) 25:394–8. doi: 10.1002/eji.1830250213 [DOI] [PubMed] [Google Scholar]
10. Tree TIM, Lawson J, Edwards H, Skowera A, Arif S, Roep BO, et al. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes (2010) 59:1451–60. doi: 10.2337/db09-0503 [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Gruarin P, Maglie S, de Simone M, Häringer B, Vasco C, Ranzani V, et al. Eomesodermin controls a unique differentiation program in human IL-10 and IFN-γ coproducing regulatory T cells. Eur J Immunol (2019) 49:96–111. doi: 10.1002/eji.201847722 [DOI] [PubMed] [Google Scholar]
12. Magnani CF, Alberigo G, Bacchetta R, Serafini G, Andreani M, Roncarolo MG, et al. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol (2011) 41:1652–62. doi: 10.1002/eji.201041120 [DOI] [PMC free article] [PubMed] [Google Scholar]
13. Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med (2008) 205:2887–98. doi: 10.1084/jem.20080193 [DOI] [PMC free article] [PubMed] [Google Scholar]
14. Chen PP, Cepika A, Agarwal-hashmi R, Saini G, Uyeda MJ, Louis DM, et al. Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. Sci Transl Med (2021) 13:eabf5264. doi: 10.1126/scitranslmed.abf5264 [DOI] [PMC free article] [PubMed] [Google Scholar]
15. Sumitomo S, Nakachi S, Okamura T, Tsuchida Y, Kato R, Shoda H, et al. Identification of tonsillar CD4+CD25–LAG3+ T cells as naturally occurring IL-10-producing regulatory T cells in human lymphoid tissue. J Autoimmun (2017) 76:75–84. doi: 10.1016/j.jaut.2016.09.005 [DOI] [PubMed] [Google Scholar]
16. Facciotti F, Gagliani N, Häringer B, Alfen JS, Penatti A, Maglie S, et al. IL-10–producing forkhead box protein 3–negative regulatory T cells inhibit b-cell responses and are involved in systemic lupus erythematosus. J Allergy Clin Immunol (2016) 137:318–321.e5. doi: 10.1016/j.jaci.2015.06.044 [DOI] [PubMed] [Google Scholar]
17. Roncarolo MG, Gregori S, Bacchetta R, Battaglia M, Gagliani N. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity (2018) 49:1004–19. doi: 10.1016/j.immuni.2018.12.001 [DOI] [PubMed] [Google Scholar]
18. Sayitoglu EC, Freeborn RA, Roncarolo MG. The yin and yang of type 1 regulatory T Cells : From discovery to clinical application. Front Immunol (2021) 12:693105. doi: 10.3389/fimmu.2021.693105 [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, et al. “Infectious” transplantation tolerance. Science (1993) 259:974–7. doi: 10.1126/science.8094901 [DOI] [PubMed] [Google Scholar]
20. Altin JA, Goodnow CC, Cook MC. IL-10 + CTLA-4 + Th2 inhibitory cells form in a Foxp3-independent, IL-2–dependent manner from Th2 effectors during chronic inflammation. J Immunol (2012) 188:5478–88. doi: 10.4049/jimmunol.1102994 [DOI] [PubMed] [Google Scholar]
21. Cope A, le Friec G, Cardone J, Kemper C. The Th1 life cycle: Molecular control of IFN-γ to IL-10 switching. Trends Immunol (2011) 32:278–86. doi: 10.1016/j.it.2011.03.010 [DOI] [PubMed] [Google Scholar]
22. Cardone J, le Friec G, Vantourout P, Roberts A, Fuchs A, Jackson I, et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol (2010) 11:862–71. doi: 10.1038/ni.1917 [DOI] [PMC free article] [PubMed] [Google Scholar]
23. Ahlers J, Mantei A, Lozza L, Stäber M, Heinrich F, Bacher P, et al. A Notch/STAT3-driven blimp-1/c-Maf-dependent molecular switch induces IL-10 expression in human CD4+ T cells and is defective in crohn´s disease patients. Mucosal Immunol (2022) 15:1–11. doi: 10.1038/s41385-022-00487-x [DOI] [PMC free article] [PubMed] [Google Scholar]
24. Tsai Y-G, Chien J-W, Chiu Y-M, Su T-C, Chiu P-F, Hsiao K-H, et al. Lupus nephritis with corticosteroid responsiveness: molecular changes of CD46-mediated type 1 regulatory T cells. Pediatr Res (2021). doi: 10.1038/s41390-021-01882-z [DOI] [PubMed] [Google Scholar]
25. Gabrysova L, Nicolson KS, Streeter HB, Verhagen J, Sabatos-Peyton CA, Morgan DJ, et al. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med (2009) 206:1755–67. doi: 10.1084/jem20082118 [DOI] [PMC free article] [PubMed] [Google Scholar]
26. Uyeda MJ, Freeborn RA, Cieniewicz B, Romano R, Chen PP, Liu JM, et al. BHLHE40 regulates IL-10 and IFN-γ production in T cells but does not interfere with human type 1 regulatory T cell differentiation. Front Immunol (2021) 12:683680. doi: 10.3389/fimmu.2021.683680 [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 19:739–46. doi: 10.1038/nm.3179 [DOI] [PubMed] [Google Scholar]
28. Häringer B, Lozza L, Steckel B, Geginat J. Identification and characterization of IL-10/IFN-γ-producing effector-like T cells with regulatory function in human blood. J Exp Med (2009) 206:1009–17. doi: 10.1084/jem.20082238 [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor egr-2. Proc Natl Acad Sci (2009) 106:13974–9. doi: 10.1073/pnas.0906872106 [DOI] [PMC free article] [PubMed] [Google Scholar]
30. Alfen JS, Larghi P, Facciotti F, Gagliani N, Bosotti R, Paroni M, et al. Intestinal IFN-γ–producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease. J Allergy Clin Immunol (2018) 142:1537–1547.e8. doi: 10.1016/j.jaci.2017.12.984 [DOI] [PubMed] [Google Scholar]
31. Brockmann L, Soukou S, Steglich B, Czarnewski P, Zhao L, Wende S, et al. Molecular and functional heterogeneity of IL-10-producing CD4 + T cells. Nat Commun (2018) 9:5457. doi: 10.1038/s41467-018-07581-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
32. Bauché D, Joyce-Shaikh B, Jain R, Grein J, Ku KS, Blumenschein WM, et al. LAG3 + regulatory T cells restrain interleukin-23-Producing CX3CR1 + gut-resident macrophages during group 3 innate lymphoid cell-driven colitis. Immunity (2018) 49:342–352.e5. doi: 10.1016/j.immuni.2018.07.007 [DOI] [PubMed] [Google Scholar]
33. Banerjee H, Nieves-rosado H, Kulkarni A, Delgoffe GM, Ferris RL, Kane LP, et al. Expression of Tim-3 drives phenotypic and functional changes in treg cells in secondary lymphoid organs and the tumor microenvironment. CellReports (2021) 36:109699. doi: 10.1016/j.celrep.2021.109699 [DOI] [PMC free article] [PubMed] [Google Scholar]
34. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, et al. The aryl hydrocarbon receptor interacts with c-maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 11:854–61. doi: 10.1038/ni.1912 [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Zhang H, Madi A, Yosef N, Chihara N, Awasthi A, Pot C, et al. An IL-27-Driven transcriptional network identifies regulators of IL-10 expression across T helper cell subsets. Cell Rep (2020) 33:108433. doi: 10.1016/j.celrep.2020.108433 [DOI] [PMC free article] [PubMed] [Google Scholar]
36. Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3+ regulatory T cells. Nat Immunol (2010) 11:846–53. doi: 10.1038/ni.1915 [DOI] [PMC free article] [PubMed] [Google Scholar]
37. Tousa S, Semitekolou M, Morianos I, Banos A, Trochoutsou AI, Brodie TM, et al. Activin-a co-opts IRF4 and AhR signaling to induce human regulatory T cells that restrain asthmatic responses. Proc Natl Acad Sci U.S.A. (2017) 114:2891–900. doi: 10.1073/pnas.1616942114 [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Roessner PM, Llaó Cid L, Lupar E, Roider T, Bordas M, Schifflers C, et al. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia (2021) 35:2311–24. doi: 10.1038/s41375-021-01136-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
39. Bonnal RJP, Rossetti G, Lugli E, de Simone M, Gruarin P, Brummelman J, et al. Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression. Nat Immunol (2021) 22:735–45. doi: 10.1038/s41590-021-00930-4 [DOI] [PubMed] [Google Scholar]
40. Baron U, Floess S, Wieczorek G, Baumann K, Grützkau A, Dong J, et al. DNA Demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells. Eur J Immunol (2007) 37:2378–89. doi: 10.1002/eji.200737594 [DOI] [PubMed] [Google Scholar]
41. Bevington SL, Ng STH, Britton GJ, Keane P, Wraith DC, Cockerill PN. Chromatin priming renders T cell tolerance-associated genes sensitive to activation below the signaling threshold for immune response genes. Cell Rep (2020) 31:107748. doi: 10.1016/j.celrep.2020.107748 [DOI] [PMC free article] [PubMed] [Google Scholar]
42. Yadava K, Medina CO, Ishak H, Gurevich I, Kuipers H, Shamskhou EA, et al. Natural tr1-like cells do not confer long-term tolerogenic memory. Elife (2019) 8:e44821. doi: 10.7554/eLife.44821 [DOI] [PMC free article] [PubMed] [Google Scholar]
43. Omokanye A, Ong LC, Lebrero-Fernandez C, Bernasconi V, Schön K, Strömberg A, et al. Clonotypic analysis of protective influenza M2e-specific lung resident Th17 memory cells reveals extensive functional diversity. Mucosal Immunol (2022) 15:717–29. doi: 10.1038/s41385-022-00497-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Gianfrani C, Levings MK, Sartirana C, Mazzarella G, Barba G, Zanzi D, et al. Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J Immunol (2006) 177:4178–86. doi: 10.4049/jimmunol.177.6.4178 [DOI] [PubMed] [Google Scholar]
45. Veldman C, Höhne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol (2004) 172:6468–75. doi: 10.4049/jimmunol.172.10.6468 [DOI] [PubMed] [Google Scholar]
46. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med (2012) 209:109–21. doi: 10.1084/jem.20110399 [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Kim JE, Sharma A, Sharma G, Lee SY, Shin HS, Rudra D, et al. Lactobacillus pentosus modulates immune response by inducing IL-10 producing Tr1 cells. Immune Netw (2019) 19:e39. doi: 10.4110/in.2019.19.e39 [DOI] [PMC free article] [PubMed] [Google Scholar]
48. Maquet C, Baiwir J, Loos P, Rodriguez-Rodriguez L, Javaux J, Sandor R, et al. Ly6Chi monocytes balance regulatory and cytotoxic CD4 T cell responses to control virus-induced immunopathology. Sci Immunol (2022) 7:eabn3240. doi: 10.1126/sciimmunol.abn3240 [DOI] [PubMed] [Google Scholar]
49. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood (2010) 116:935–44. doi: 10.1182/blood-2011-08-377416 [DOI] [PubMed] [Google Scholar]
50. Mfarrej B, Jofra T, Morsiani C, Gagliani N, Fousteri G, Battaglia M. Key role of macrophages in tolerance induction via T regulatory type 1 (Tr1) cells. Clin Exp Immunol (2020) 201:222–30. doi: 10.1111/cei.13440 [DOI] [PMC free article] [PubMed] [Google Scholar]
51. Wakkach A, Cottrez F, Groux H. Differentiation of regulatory T cells 1 is induced by CD2 costimulation. J Immunol (2001) 167:3107–13. doi: 10.4049/jimmunol.167.6.3107 [DOI] [PubMed] [Google Scholar]
52. Sutavani RV, Bradley RG, Ramage JM, Jackson AM, Durrant LG, Spendlove I. CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype. J Immunol (2013) 191:5895–903. doi: 10.4049/jimmunol.1301458 [DOI] [PubMed] [Google Scholar]
53. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med (2007) 204:105–15. doi: 10.1084/jem.20061660 [DOI] [PMC free article] [PubMed] [Google Scholar]
54. Ding Q, Lu L, Wang B, Zhou Y, Jiang Y, Zhou X, et al. B7H1-ig fusion protein activates the CD4 + IFN-γ receptor + type 1 T regulatory subset through IFN-γ-Secreting Th1 cells. J Immunol (2006) 177:3606–14. doi: 10.4049/jimmunol.177.6.3606 [DOI] [PubMed] [Google Scholar]
55. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 421:388–92. doi: 10.1038/nature01315 [DOI] [PubMed] [Google Scholar]
56. le Friec G, Sheppard D, Whiteman P, Karsten CM, Shamoun SAT, Laing A, et al. The CD46-Jagged1 interaction is critical for human T h 1 immunity. Nat Immunol (2012) 13:1213–21. doi: 10.1038/ni.2454 [DOI] [PMC free article] [PubMed] [Google Scholar]
57. Choileain SN, Hay J, Thomas J, Williams A, Vermeren MM, Benezech C, et al. TCR-stimulated changes in cell surface CD46 expression generate type 1 regulatory T cells. Sci Signal (2017) 10:1–13. doi: 10.1126/scisignal.aah6163 [DOI] [PubMed] [Google Scholar]
58. Brockmann L, Gagliani N, Steglich B, Giannou AD, Kempski J, Pelczar P, et al. IL-10 receptor signaling is essential for TR1 cell function In vivo . J Immunol (2017) 198:1130–41. doi: 10.4049/jimmunol.1601045 [DOI] [PMC free article] [PubMed] [Google Scholar]
59. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo M-G. IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol (2001) 166:5530–9. doi: 10.4049/jimmunol.166.9.5530 [DOI] [PubMed] [Google Scholar]
60. Zhang P, Lee JS, Gartlan KH, Schuster IS, Comerford I, Varelias A, et al. Eomesodermin promotes the development of type 1 regulatory T (TR1) cells. Sci Immunol (2017) 2:eaah7152. doi: 10.1126/sciimmunol.aah7152 [DOI] [PMC free article] [PubMed] [Google Scholar]
61. Awasthi A, Carrier Y, Peron JPS, Bettelli E, Kamanaka M, Flavell RA, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 8:1380–9. doi: 10.1038/ni1541 [DOI] [PubMed] [Google Scholar]
62. Pot C, Jin H, Awasthi A, Liu SM, Lai C-Y, Madan R, et al. Cutting edge: IL-27 induces the transcription factor c-maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-Producing Tr1 cells. J Immunol (2009) 183:797–801. doi: 10.4049/jimmunol.0901233 [DOI] [PMC free article] [PubMed] [Google Scholar]
63. Sumida TS, Dulberg S, Schupp JC, Lincoln MR, Stillwell HA, Axisa P, et al. Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat Immunol (2022) 23:632–42. doi: 10.1038/s41590-022-01152-y [DOI] [PMC free article] [PubMed] [Google Scholar]
64. Bacchetta R, Gregori S, Serafini G, Sartirana C, Schulz U, Zino E, et al. Molecular and functional characterization of allogantigen specific anergic T cells suitable for cell therapy. Haematologica (2010) 95:2134–43. doi: 10.3324/haematol.2010.025825 [DOI] [PMC free article] [PubMed] [Google Scholar]
65. Farez MF, Mascanfroni ID, Méndez-Huergo SP, Yeste A, Murugaiyan G, Garo LP, et al. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell (2015) 162:1338–52. doi: 10.1016/j.cell.2015.08.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
66. Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR / Cas9-mediated gene knockout in primary T cells. J Exp Med (2018) 215:985–97. doi: 10.1084/jem.20171626 [DOI] [PMC free article] [PubMed] [Google Scholar]
67. Shifrut E, Carnevale J, Tobin V, Roth TL, Woo JM, Bui CT, et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell (2018) 175:1958–1971.e15. doi: 10.1016/j.cell.2018.10.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
68. Schmidt R, Steinhart Z, Layeghi M, Freimer JW, Nguyen VQ, Blaeschke F, et al. CRISPR activation and interference screens in primary human T cells decode cytokine regulation. Science (2022) 375:eabj4008. doi: 10.1126/science.abj4008 [DOI] [PMC free article] [PubMed] [Google Scholar]
69. Cook L, Stahl M, Han X, Nazli A, MacDonald KN, Wong MQ, et al. Suppressive and gut-reparative functions of human type 1 T regulatory cells. Gastroenterology (2019) 157:1584–98. doi: 10.1053/j.gastro.2019.09.002 [DOI] [PubMed] [Google Scholar]
70. Liu JM-H, Chen P, Uyeda MJ, Cieniewicz B, Sayitoglu EC, Thomas BC, et al. Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy. Cytotherapy (2021) 23:10174–1028. doi: 10.1016/j.jcyt.2021.05.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
71. Amodio G, Mugione A, Sanchez AM, Viganò P, Candiani M, Somigliana E, et al. HLA-G expressing DC-10 and CD4+ T cells accumulate in human decidua during pregnancy. Hum Immunol (2013) 74:406–11. doi: 10.1016/j.humimm.2012.11.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
72. Salvany-Celades M, van der Zwan A, Benner M, Setrajcic-Dragos V, Bougleux Gomes HA, Iyer V, et al. Three types of functional regulatory T cells control T cell responses at the human maternal-fetal interface. Cell Rep (2019) 27:2537–47. doi: 10.1016/j.celrep.2019.04.109 [DOI] [PubMed] [Google Scholar]
73. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 75:263–74. doi: 10.1016/0092-8674(93)80068-P [DOI] [PubMed] [Google Scholar]
74. Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum (2000) 43:617–27. doi: 10.1002/1529-0131(200003)43:3<617::AID-ANR19>3.0.CO;2-B [DOI] [PubMed] [Google Scholar]
75. Wang L, Wang F-S, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med (2015) 278:369–95. doi: 10.1111/joim.12395 [DOI] [PubMed] [Google Scholar]
76. Yu H, Gagliani N, Ishigame H, Huber S, Zhu S, Esplugues E, et al. Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development. Proc Natl Acad Sci (2017) 114:10443–8. doi: 10.1073/pnas.1705599114 [DOI] [PMC free article] [PubMed] [Google Scholar]
77. Battaglia M, Stabilini A, Draghici E, Migliavacca B, Gregori S, Bonifacio E, et al. Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes (2006) 55:1571–80. doi: 10.2337/db05-1576 [DOI] [PubMed] [Google Scholar]
78. Chen C, Lee W-H, Yun P, Snow P, Liu C-P. Induction of autoantigen-specific Th2 and Tr1 regulatory T cells and modulation of autoimmune diabetes. J Immunol (2003) 171:733–44. doi: 10.4049/jimmunol.171.2.733 [DOI] [PubMed] [Google Scholar]
79. Prasad S, Neef T, Xu D, Podojil JR, Getts DR, Shea LD, et al. Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells. J Autoimmun (2018) 89:112–24. doi: 10.1016/j.jaut.2017.12.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
80. Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature (2016) 530:434–40. doi: 10.1038/nature16962 [DOI] [PubMed] [Google Scholar]
81. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest (2004) 113:451–63. doi: 10.1172/JCI19585 [DOI] [PMC free article] [PubMed] [Google Scholar]
82. Petrich de Marquesini LG, Fu J, Connor KJ, Bishop AJ, McLintock NE, Pope C, et al. IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia (2010) 53:1451–60. doi: 10.1007/s00125-010-1739-3 [DOI] [PubMed] [Google Scholar]
83. Sanda S, Roep BO, von Herrath M. Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. Clin Immunol (2008) 127:138–43. doi: 10.1016/j.clim.2007.12.003 [DOI] [PubMed] [Google Scholar]
84. Chujo D, Nguyen T-S, Foucat E, Blankenship D, Banchereau J, Nepom GT, et al. Adult-onset type 1 diabetes patients display decreased IGRP-specific Tr1 cells in blood. Clin Immunol (2015) 161:270–7. doi: 10.1016/j.clim.2015.08.014 [DOI] [PubMed] [Google Scholar]
85. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-ala). J Clin Invest (2003) 111:409–18. doi: 10.1172/JCI16090 [DOI] [PMC free article] [PubMed] [Google Scholar]
86. Alhadj Ali M, Liu Y-F, Arif S, Tatovic D, Shariff H, Gibson VB, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med (2017) 9:eaaf7779. doi: 10.1126/scitranslmed.aaf7779 [DOI] [PubMed] [Google Scholar]
87. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, et al. In vitro generation of interleukin 10–producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)– and Th2-inducing cytokines. J Exp Med (2002) 195:603–16. doi: 10.1084/jem.20011629 [DOI] [PMC free article] [PubMed] [Google Scholar]
88. Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol (2013) 14:1054–63. doi: 10.1038/ni.2695 [DOI] [PMC free article] [PubMed] [Google Scholar]
89. Raverdeau M, Christofi M, Malara A, Wilk MM, Misiak A, Kuffova L, et al. Retinoic acid-induced autoantigen-specific type 1 regulatory T cells suppress autoimmunity. EMBO Rep (2019) 20:e47121. doi: 10.15252/embr.201847121 [DOI] [PMC free article] [PubMed] [Google Scholar]
90. Kenison JE, Jhaveri A, Li Z, Khadse N, Tjon E, Tezza S, et al. Tolerogenic nanoparticles suppress central nervous system inflammation. Proc Natl Acad Sci (2020) 117:32017–28. doi: 10.1073/pnas.2016451117 [DOI] [PMC free article] [PubMed] [Google Scholar]
91. Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest (2006) 116:3252–7. doi: 10.1172/JCI29251 [DOI] [PMC free article] [PubMed] [Google Scholar]
92. Caielli S, Veiga DT, Balasubramanian P, Athale S, Domic B, Murat E, et al. A CD4+ T cell population expanded in lupus blood provides b cell help through interleukin-10 and succinate. Nat Med (2019) 25:75–81. doi: 10.1038/s41591-018-0254-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
93. Asnagli H, Martire D, Belmonte N, Quentin J, Bastian H, Boucard-Jourdin M, et al. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Arthritis Res Ther (2014) 16:R115. doi: 10.1186/ar4567 [DOI] [PMC free article] [PubMed] [Google Scholar]
94. Kim J, Lee J, Gonzalez J, Fuentes-Duculan J, Garcet S, Krueger JG. Proportion of CD4+CD49b+LAG-3+ type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index. J Invest Dermatol (2018) 138:2669–72. doi: 10.1016/j.jid.2018.05.021 [DOI] [PubMed] [Google Scholar]
95. Kelly CP, Murray JA, Leffler DA, Getts DR, Bledsoe AC, Smithson G, et al. TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: A randomized, double-blind, placebo-controlled study. Gastroenterology (2021) 161:66–80.e8. doi: 10.1053/j.gastro.2021.03.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
96. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med (1999) 190:995–1004. doi: 10.1084/jem.190.7.995 [DOI] [PMC free article] [PubMed] [Google Scholar]
97. Huber S, Gagliani N, Esplugues E, O’Connor W, Huber FJ, Chaudhry A, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3– and Foxp3+ regulatory CD4+ T cells in an interleukin-10-Dependent manner. Immunity (2011) 34:554–65. doi: 10.1016/j.immuni.2011.01.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
98. Doñas C, Neira J, Osorio-Barrios F, Carrasco M, Fernández D, Prado C, et al. The demethylase inhibitor GSK-J4 limits inflammatory colitis by promoting de novo synthesis of retinoic acid in dendritic cells. Sci Rep (2021) 11:1342. doi: 10.1038/s41598-020-79122-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
99. Qi L, Wu J, Zhu S, Wang X, Lv X, Liu C, et al. Mesenchymal stem cells alleviate inflammatory bowel disease Via Tr1 cells. Stem Cell Rev Rep (2022) 18:2444–57. doi: 10.1007/s12015-022-10353-9 [DOI] [PubMed] [Google Scholar]
100. Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory crohn’s disease. Gastroenterology (2012) 143:1207–1217.e2. doi: 10.1053/j.gastro.2012.07.116 [DOI] [PubMed] [Google Scholar]
101. Chatenoud L, Ferran C, Bach J-F. The anti-CD3-Induced syndrome: A consequence of massive In vivo cell activation. In: Fleischer B, Sjögren HO (eds) Superantigens. Current Topics in Microbiology and Immunology. (Berlin, Heidelberg: Springer) 174. (1991), 121–34. doi: 10.1007/978-3-642-50998-8_9 [DOI] [PubMed] [Google Scholar]
102. Jamison BL, Neef T, Goodspeed A, Bradley B, Baker RL, Miller SD, et al. Nanoparticles containing an insulin–ChgA hybrid peptide protect from transfer of autoimmune diabetes by shifting the balance between effector T cells and regulatory T cells. J Immunol (2019) 203:48–57. doi: 10.4049/jimmunol.1900127 [DOI] [PMC free article] [PubMed] [Google Scholar]
103. Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol (2012) 30:1217–24. doi: 10.1038/nbt.2434 [DOI] [PMC free article] [PubMed] [Google Scholar]
104. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol (2020) 5:17–30. doi: 10.1016/S2468-1253(19)30333-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
105. Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, et al. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol (2006) 177:5852–60. doi: 10.4049/jimmunol.177.9.5852 [DOI] [PMC free article] [PubMed] [Google Scholar]
106. Kamanaka M, Kim ST, Wan YY, Sutterwala FS, Lara-Tejero M, Galán JE, et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity (2006) 25:941–52. doi: 10.1016/j.immuni.2006.09.013 [DOI] [PubMed] [Google Scholar]
107. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3– precursor cells in the absence of interleukin 10. Nat Immunol (2007) 8:931–41. doi: 10.1038/ni1504 [DOI] [PubMed] [Google Scholar]
108. Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK. Regulatory T-cell therapy for inflammatory bowel disease: More questions than answers. Immunology (2012) 136:115–22. doi: 10.1111/j.1365-2567.2012.03572.x [DOI] [PMC free article] [PubMed] [Google Scholar]
109. Asseman C, Read S, Powrie F. Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: Control by CD4 ⁺ regulatory T cells and IL-10. J Immunol (2003) 171:971–8. doi: 10.4049/jimmunol.171.2.971 [DOI] [PubMed] [Google Scholar]
110. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity (2008) 28:546–58. doi: 10.1016/j.immuni.2008.02.017 [DOI] [PubMed] [Google Scholar]
111. Roers A, Siewe L, Strittmatter E, Deckert M, Schlüter D, Stenzel W, et al. T Cell–specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med (2004) 200:1289–97. doi: 10.1084/jem.20041789 [DOI] [PMC free article] [PubMed] [Google Scholar]
112. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich J-M, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity (2011) 34:566–78. doi: 10.1016/j.immuni.2011.03.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
113. McGuirk P, McCann C, Mills KHG. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: A novel strategy for evasion of protective T helper type 1 responses by bordetella pertussis. J Exp Med (2002) 195:221–31. doi: 10.1084/jem.20011288 [DOI] [PMC free article] [PubMed] [Google Scholar]
114. Jofra T, di Fonte R, Galvani G, Kuka M, Iannacone M, Battaglia M, et al. Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection. Eur J Immunol (2018) 48:1389–99. doi: 10.1002/eji.201747316 [DOI] [PubMed] [Google Scholar]
115. Eliasson DG, Omokanye A, Schön K, Wenzel UA, Bernasconi V, Bemark M, et al. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection. Mucosal Immunol (2018) 11:273–89. doi: 10.1038/mi.2017.14 [DOI] [PubMed] [Google Scholar]
116. Antunes I, Kassiotis G. Suppression of innate immune pathology by regulatory T cells during influenza a virus infection of immunodeficient mice. J Virol (2010) 84:12564–75. doi: 10.1128/jvi.01559-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
117. Brincks EL, Roberts AD, Cookenham T, Kohlmeier JE, Blackman MA, David L. Antigen-specific memory regulatory CD4 + Foxp3 + T cells control memory responses to influenza virus infection. J Immunol (2013) 190:3438–46. doi: 10.4049/jimmunol.1203140 [DOI] [PMC free article] [PubMed] [Google Scholar]
118. Moser EK, Hufford MM, Braciale TJ. Late engagement of CD86 after influenza virus clearance promotes recovery in a FoxP3 + regulatory T cell dependent manner. PloS Pathog (2014) 10:e1004315. doi: 10.1371/journal.ppat.1004315 [DOI] [PMC free article] [PubMed] [Google Scholar]
119. Rogers MC, Lamens KD, Shafagati N, Johnson M, Oury TD, Joyce S, et al. CD4 + regulatory T cells exert differential functions during early and late stages of the immune response to respiratory viruses. J Immunol (2018) 201:1253–66. doi: 10.4049/jimmunol.1800096 [DOI] [PMC free article] [PubMed] [Google Scholar]
120. Lu C, Zanker D, Lock P, Jiang X, Deng J, Duan M, et al. Memory regulatory T cells home to the lung and control influenza a virus infection. Immunol Cell Biol (2019) 97:774–86. doi: 10.1111/imcb.12271 [DOI] [PubMed] [Google Scholar]
121. Doetze A, Satoguina J, Burchard G, Rau T, Loliger C, Fleischer B, et al. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. Int Immunol (2000) 12:623–30. [DOI] [PubMed] [Google Scholar]
122. Koch K, Koch N, Sandaradura De Silva U, Jung N, Schulze Zur Wiesch J, Fatkenheuer G, et al. Increased frequency of CD49b/LAG-3+ type 1 regulatory T cells in HIV-infected individuals. AIDS Res Hum Retroviruses (2015) 31:1238–46. doi: 10.1089/aid.2014.0356 [DOI] [PubMed] [Google Scholar]
123. Moreira Genaro L, de Oliveira Coser L, da Silva Justo Junior A, Furquim de Castro L, Felício Barreto AK, Rizzato AE, et al. Association between IL-27 and Tr1 cells in severe form of paracoccidioidomycosis. Cytokine (2020) 127:154962. doi: 10.1016/j.cyto.2019.154962 [DOI] [PubMed] [Google Scholar]
124. MacDonald AJ, Duffy M, Brady MT, McKiernan S, Hall W, Hegarty J, et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis c virus-infected persons. J Infect Dis (2002) 185:720–7. doi: 10.1086/339340 [DOI] [PubMed] [Google Scholar]
125. Brady MT, MacDonald AJ, Rowan AG, Mills KHG. Hepatitis c virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol (2003) 33:3448–57. doi: 10.1002/eji.200324251 [DOI] [PubMed] [Google Scholar]
126. Carpentier A, Conti F, Stenard F, Aoudjehane L, Miroux C, Podevin P, et al. Increased expression of regulatory Tr1 cells in recurrent hepatitis c after liver transplantation. Am J Transplant (2009) 9:2102–12. doi: 10.1111/j.1600-6143.2009.02743.x [DOI] [PubMed] [Google Scholar]
127. Fabien S, Olivier M, Khaldoun G, Vivian V, Lynda A, Laurissa O, et al. CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis c after liver transplantation. BioMed Res Int (2014) 2014:290878. doi: 10.1155/2014/290878 [DOI] [PMC free article] [PubMed] [Google Scholar]
128. Utsumi M, Takaki A, Umeda Y, Koike K, Napier SC, Watanabe N, et al. Frequency of regulatory T-cell and hepatitis c viral antigen-specific immune response in recurrent hepatitis c after liver transplantation. Transpl Immunol (2014) 31:33–41. doi: 10.1016/j.trim.2014.05.006 [DOI] [PubMed] [Google Scholar]
129. Ghazal K, Morales O, Barjon C, Dahlqvist G, Aoudjehane L, Ouaguia L, et al. Early high levels of regulatory T cells and T helper 1 may predict the progression of recurrent hepatitis c after liver transplantation. Clin Res Hepatol Gastroenterol (2019) 43:273–81. doi: 10.1016/j.clinre.2018.10.005 [DOI] [PubMed] [Google Scholar]
130. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: More questions than answers. Nat Immunol (2008) 9:725–32. doi: 10.1038/ni.f.205 [DOI] [PubMed] [Google Scholar]
131. Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, Kamya MR, Rosenthal PJ, Rek J, et al. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure. Elife (2018) 7:e35832. doi: 10.7554/eLife.35832 [DOI] [PMC free article] [PubMed] [Google Scholar]
132. Jagannathan P, Eccles-James I, Bowen K, Nankya F, Auma A, Wamala S, et al. IFNγ/IL-10 Co-producing cells dominate the CD4 response to malaria in highly exposed children. PloS Pathog (2014) 10:e1003864. doi: 10.1371/journal.ppat.1003864 [DOI] [PMC free article] [PubMed] [Google Scholar]
133. Freitas do Rosário AP, Lamb T, Spence P, Stephens R, Lang A, Roers A, et al. IL-27 promotes IL-10 production by effector Th1 CD4 + T cells: A critical mechanism for protection from severe immunopathology during malaria infection. J Immunol (2012) 188:1178–90. doi: 10.4049/jimmunol.1102755 [DOI] [PMC free article] [PubMed] [Google Scholar]
134. Loevenich K, Ueffing K, Abel S, Hose M, Matuschewski K, Westendorf AM, et al. DC-Derived IL-10 modulates pro-inflammatory cytokine production and promotes induction of CD4+IL-10+ regulatory T cells during plasmodium yoelii infection. Front Immunol (2017) 8:152. doi: 10.3389/fimmu.2017.00152 [DOI] [PMC free article] [PubMed] [Google Scholar]
135. Abel S, Lückheide N, Westendorf AM, Geffers R, Roers A, Müller W, et al. Strong impact of CD4+ Foxp3+ regulatory T cells and limited effect of T cell-derived IL-10 on pathogen clearance during plasmodium yoelii infection. J Immunol (2012) 188:5467–77. doi: 10.4049/jimmunol.1102223 [DOI] [PubMed] [Google Scholar]
136. Couper KN, Blount DG, Wilson MS, Hafalla JC, Belkaid Y, Kamanaka M, et al. IL-10 from CD4+CD25-Foxp3-CD127 - adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection. PloS Pathog (2008) 4:e1000004. doi: 10.1371/journal.ppat.1000004 [DOI] [PMC free article] [PubMed] [Google Scholar]
137. Lönnberg T, Svensson V, James KR, Fernandez-Ruiz D, Sebina I, Montandon R, et al. Single-cell RNA-seq and computational analysis using temporal mixture modeling resolves TH1/TFH fate bifurcation in malaria. Sci Immunol (2017) 2:eaal2192. doi: 10.1126/sciimmunol.aal2192 [DOI] [PMC free article] [PubMed] [Google Scholar]
138. Soon MSF, Lee HJ, Engel JA, Straube J, Thomas BS, Pernold CPS, et al. Transcriptome dynamics of CD4+ T cells during malaria maps gradual transit from effector to memory. Nat Immunol (2020) 21:1597–610. doi: 10.1038/s41590-020-0800-8 [DOI] [PubMed] [Google Scholar]
139. Neumann C, Scheffold A, Rutz S. Functions and regulation of T cell-derived interleukin-10. Semin Immunol (2019) 44:101344. doi: 10.1016/j.smim.2019.101344 [DOI] [PubMed] [Google Scholar]
140. Boyle MJ, Jagannathan P, Bowen K, McIntyre TI, Vance HM, Farrington LA, et al. The development of plasmodium falciparum-specific IL10 CD4 T cells and protection from malaria in children in an area of high malaria transmission. Front Immunol (2017) 8:1329. doi: 10.3389/fimmu.2017.01329 [DOI] [PMC free article] [PubMed] [Google Scholar]
141. Mackroth MS, Abel A, Steeg C, Schulze zur Wiesch J, Jacobs T. Acute malaria induces PD1+CTLA4+ effector T cells with cell-extrinsic suppressor function. PloS Pathog (2016) 12:1–24. doi: 10.1371/journal.ppat.1005909 [DOI] [PMC free article] [PubMed] [Google Scholar]
142. Brandi J, Lehmann C, Kaminski LC, Schulze zur Wiesch J, Addo M, Ramharter M, et al. T Cells expressing multiple co-inhibitory molecules in acute malaria are not exhausted but exert a suppressive function in mice. Eur J Immunol (2022) 52:312–27. doi: 10.1002/eji.202149424 [DOI] [PubMed] [Google Scholar]
143. Brandi J, Riehn M, Hadjilaou A, Jacobs T. Increased expression of multiple Co-inhibitory molecules on malaria-induced CD8+ T cells are associated with increased function instead of exhaustion. Front Immunol (2022) 13:878320. doi: 10.3389/fimmu.2022.878320 [DOI] [PMC free article] [PubMed] [Google Scholar]
144. Christoffersson G, von Herrath M. Regulatory immune mechanisms beyond regulatory T cells. Trends Immunol (2019) 40:482–91. doi: 10.1016/j.it.2019.04.005 [DOI] [PubMed] [Google Scholar]
145. Passerini L, di Nunzio S, Gregori S, Gambineri E, Cecconi M, Seidel MG, et al. Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur J Immunol (2011) 41:1120–31. doi: 10.1002/eji.201040909 [DOI] [PMC free article] [PubMed] [Google Scholar]
146. Narula M, Lakshmanan U, Borna S, Schulze JJ, Holmes TH, Harre N, et al. Epigenetic and immunological indicators of IPEX disease in subjects with FOXP3 gene mutation. J Allergy Clin Immunol (2022). doi: 10.1016/j.jaci.2022.09.013 [DOI] [PubMed] [Google Scholar]
147. Lio CWJ, Hsieh CS. Becoming self-aware: The thymic education of regulatory T cells. Curr Opin Immunol (2011) 23:213–9. doi: 10.1016/j.coi.2010.11.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
148. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med (2004) 199:1567–75. doi: 10.1084/jem.20032058 [DOI] [PMC free article] [PubMed] [Google Scholar]
149. Pacciani V, Gregori S, Chini L, Corrente S, Chianca M, Moschese V, et al. Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites. J Allergy Clin Immunol (2010) 125:727–36. doi: 10.1016/j.jaci.2009.12.004 [DOI] [PubMed] [Google Scholar]
150. Pellerin L, Jenks JA, Chinthrajah S, Dominguez T, Block W, Zhou X, et al. Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired. J Allergy Clin Immunol (2018) 141:202–213.e8. doi: 10.1016/j.jaci.2017.05.045 [DOI] [PubMed] [Google Scholar]
151. Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer J-P, Groux H. A comparative study between T regulatory type 1 and CD4+CD25+ T cells in the control of inflammation. J Immunol (2003) 171:5018–26. doi: 10.4049/jimmunol.171.10.5018 [DOI] [PubMed] [Google Scholar]
152. Feunou P, Poulin L, Habran C, le Moine A, Goldman M, Braun MY. CD4+ CD25+ and CD4+ CD25– T cells act respectively as inducer and effector T suppressor cells in superantigen-induced tolerance. J Immunol (2003) 171:3475–84. doi: 10.4049/jimmunol.171.7.3475 [DOI] [PubMed] [Google Scholar]
153. Grundström S, Cederbom L, Sundstedt A, Scheipers P, Ivars F. Superantigen-induced regulatory T cells display different suppressive functions in the presence or absence of natural CD4+ CD25+ regulatory T cells In vivo . J Immunol (2003) 170:5008–17. doi: 10.4049/jimmunol.170.10.5008 [DOI] [PubMed] [Google Scholar]

[B1] 1. Bluestone JA, Anderson M. Tolerance in the age of immunotherapy. New Engl J Med (2020) 383:1156–66. doi: 10.1056/nejmra1911109 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B2] 2. Roncarolo MG, Yssel H, Touraine J-L, Bacchetta R, Gebuhrer L, de Vries JE, et al. Antigen recognition by MHC-incompatible cells of a human mismatched chimera. J Exp Med (1988) 168:2139–51. doi: 10.1084/jem.168.6.2139 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B3] 3. Bacchetta R, Bigler M, Touraine J-L, Parkman R, Tovo P-A, Abrams J, et al. High levels of interleukin 10 production In vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med (1994) 179:493–502. doi: 10.1084/jem.179.2.493 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B4] 4. Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 389:737–42. doi: 10.1038/39614 [DOI] [PubMed] [Google Scholar]

[B5] 5. Bacchetta R, Sartirana C, Levings MK, Bordignon C, Narula S, Roncarolo MG. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol (2002) 32:2237–45. doi: 10.1002/1521-4141(200208)32:8<2237::AID-IMMU2237>3.0.CO;2-2 [DOI] [PubMed] [Google Scholar]

[B6] 6. de Waal-Malefyt R, Haanen J, Spits H, Roncarolo M-G, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med (1991) 174:915–24. doi: 10.1084/jem.174.4.915 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B7] 7. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol (1993) 151:1224–34. [PubMed] [Google Scholar]

[B8] 8. Willems F, Marchant A, Delville J-P, Gerard C, Delvaux A, Velu T, et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocyt es. Eur J Immunol (1994) 24:1007–9. doi: 10.1002/eji.1830240435 [DOI] [PubMed] [Google Scholar]

[B9] 9. Chang C-H, Furue M, Tamaki K. B7-1 expression of langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-y or by int erleukin-10. Eur J Immunol (1995) 25:394–8. doi: 10.1002/eji.1830250213 [DOI] [PubMed] [Google Scholar]

[B10] 10. Tree TIM, Lawson J, Edwards H, Skowera A, Arif S, Roep BO, et al. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes (2010) 59:1451–60. doi: 10.2337/db09-0503 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B11] 11. Gruarin P, Maglie S, de Simone M, Häringer B, Vasco C, Ranzani V, et al. Eomesodermin controls a unique differentiation program in human IL-10 and IFN-γ coproducing regulatory T cells. Eur J Immunol (2019) 49:96–111. doi: 10.1002/eji.201847722 [DOI] [PubMed] [Google Scholar]

[B12] 12. Magnani CF, Alberigo G, Bacchetta R, Serafini G, Andreani M, Roncarolo MG, et al. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol (2011) 41:1652–62. doi: 10.1002/eji.201041120 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B13] 13. Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med (2008) 205:2887–98. doi: 10.1084/jem.20080193 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B14] 14. Chen PP, Cepika A, Agarwal-hashmi R, Saini G, Uyeda MJ, Louis DM, et al. Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. Sci Transl Med (2021) 13:eabf5264. doi: 10.1126/scitranslmed.abf5264 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B15] 15. Sumitomo S, Nakachi S, Okamura T, Tsuchida Y, Kato R, Shoda H, et al. Identification of tonsillar CD4+CD25–LAG3+ T cells as naturally occurring IL-10-producing regulatory T cells in human lymphoid tissue. J Autoimmun (2017) 76:75–84. doi: 10.1016/j.jaut.2016.09.005 [DOI] [PubMed] [Google Scholar]

[B16] 16. Facciotti F, Gagliani N, Häringer B, Alfen JS, Penatti A, Maglie S, et al. IL-10–producing forkhead box protein 3–negative regulatory T cells inhibit b-cell responses and are involved in systemic lupus erythematosus. J Allergy Clin Immunol (2016) 137:318–321.e5. doi: 10.1016/j.jaci.2015.06.044 [DOI] [PubMed] [Google Scholar]

[B17] 17. Roncarolo MG, Gregori S, Bacchetta R, Battaglia M, Gagliani N. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity (2018) 49:1004–19. doi: 10.1016/j.immuni.2018.12.001 [DOI] [PubMed] [Google Scholar]

[B18] 18. Sayitoglu EC, Freeborn RA, Roncarolo MG. The yin and yang of type 1 regulatory T Cells : From discovery to clinical application. Front Immunol (2021) 12:693105. doi: 10.3389/fimmu.2021.693105 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B19] 19. Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, et al. “Infectious” transplantation tolerance. Science (1993) 259:974–7. doi: 10.1126/science.8094901 [DOI] [PubMed] [Google Scholar]

[B20] 20. Altin JA, Goodnow CC, Cook MC. IL-10 + CTLA-4 + Th2 inhibitory cells form in a Foxp3-independent, IL-2–dependent manner from Th2 effectors during chronic inflammation. J Immunol (2012) 188:5478–88. doi: 10.4049/jimmunol.1102994 [DOI] [PubMed] [Google Scholar]

[B21] 21. Cope A, le Friec G, Cardone J, Kemper C. The Th1 life cycle: Molecular control of IFN-γ to IL-10 switching. Trends Immunol (2011) 32:278–86. doi: 10.1016/j.it.2011.03.010 [DOI] [PubMed] [Google Scholar]

[B22] 22. Cardone J, le Friec G, Vantourout P, Roberts A, Fuchs A, Jackson I, et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol (2010) 11:862–71. doi: 10.1038/ni.1917 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B23] 23. Ahlers J, Mantei A, Lozza L, Stäber M, Heinrich F, Bacher P, et al. A Notch/STAT3-driven blimp-1/c-Maf-dependent molecular switch induces IL-10 expression in human CD4+ T cells and is defective in crohn´s disease patients. Mucosal Immunol (2022) 15:1–11. doi: 10.1038/s41385-022-00487-x [DOI] [PMC free article] [PubMed] [Google Scholar]

[B24] 24. Tsai Y-G, Chien J-W, Chiu Y-M, Su T-C, Chiu P-F, Hsiao K-H, et al. Lupus nephritis with corticosteroid responsiveness: molecular changes of CD46-mediated type 1 regulatory T cells. Pediatr Res (2021). doi: 10.1038/s41390-021-01882-z [DOI] [PubMed] [Google Scholar]

[B25] 25. Gabrysova L, Nicolson KS, Streeter HB, Verhagen J, Sabatos-Peyton CA, Morgan DJ, et al. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med (2009) 206:1755–67. doi: 10.1084/jem20082118 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B26] 26. Uyeda MJ, Freeborn RA, Cieniewicz B, Romano R, Chen PP, Liu JM, et al. BHLHE40 regulates IL-10 and IFN-γ production in T cells but does not interfere with human type 1 regulatory T cell differentiation. Front Immunol (2021) 12:683680. doi: 10.3389/fimmu.2021.683680 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B27] 27. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 19:739–46. doi: 10.1038/nm.3179 [DOI] [PubMed] [Google Scholar]

[B28] 28. Häringer B, Lozza L, Steckel B, Geginat J. Identification and characterization of IL-10/IFN-γ-producing effector-like T cells with regulatory function in human blood. J Exp Med (2009) 206:1009–17. doi: 10.1084/jem.20082238 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B29] 29. Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor egr-2. Proc Natl Acad Sci (2009) 106:13974–9. doi: 10.1073/pnas.0906872106 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B30] 30. Alfen JS, Larghi P, Facciotti F, Gagliani N, Bosotti R, Paroni M, et al. Intestinal IFN-γ–producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease. J Allergy Clin Immunol (2018) 142:1537–1547.e8. doi: 10.1016/j.jaci.2017.12.984 [DOI] [PubMed] [Google Scholar]

[B31] 31. Brockmann L, Soukou S, Steglich B, Czarnewski P, Zhao L, Wende S, et al. Molecular and functional heterogeneity of IL-10-producing CD4 + T cells. Nat Commun (2018) 9:5457. doi: 10.1038/s41467-018-07581-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B32] 32. Bauché D, Joyce-Shaikh B, Jain R, Grein J, Ku KS, Blumenschein WM, et al. LAG3 + regulatory T cells restrain interleukin-23-Producing CX3CR1 + gut-resident macrophages during group 3 innate lymphoid cell-driven colitis. Immunity (2018) 49:342–352.e5. doi: 10.1016/j.immuni.2018.07.007 [DOI] [PubMed] [Google Scholar]

[B33] 33. Banerjee H, Nieves-rosado H, Kulkarni A, Delgoffe GM, Ferris RL, Kane LP, et al. Expression of Tim-3 drives phenotypic and functional changes in treg cells in secondary lymphoid organs and the tumor microenvironment. CellReports (2021) 36:109699. doi: 10.1016/j.celrep.2021.109699 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B34] 34. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, et al. The aryl hydrocarbon receptor interacts with c-maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 11:854–61. doi: 10.1038/ni.1912 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B35] 35. Zhang H, Madi A, Yosef N, Chihara N, Awasthi A, Pot C, et al. An IL-27-Driven transcriptional network identifies regulators of IL-10 expression across T helper cell subsets. Cell Rep (2020) 33:108433. doi: 10.1016/j.celrep.2020.108433 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B36] 36. Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3+ regulatory T cells. Nat Immunol (2010) 11:846–53. doi: 10.1038/ni.1915 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B37] 37. Tousa S, Semitekolou M, Morianos I, Banos A, Trochoutsou AI, Brodie TM, et al. Activin-a co-opts IRF4 and AhR signaling to induce human regulatory T cells that restrain asthmatic responses. Proc Natl Acad Sci U.S.A. (2017) 114:2891–900. doi: 10.1073/pnas.1616942114 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B38] 38. Roessner PM, Llaó Cid L, Lupar E, Roider T, Bordas M, Schifflers C, et al. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia (2021) 35:2311–24. doi: 10.1038/s41375-021-01136-1 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B39] 39. Bonnal RJP, Rossetti G, Lugli E, de Simone M, Gruarin P, Brummelman J, et al. Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression. Nat Immunol (2021) 22:735–45. doi: 10.1038/s41590-021-00930-4 [DOI] [PubMed] [Google Scholar]

[B40] 40. Baron U, Floess S, Wieczorek G, Baumann K, Grützkau A, Dong J, et al. DNA Demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells. Eur J Immunol (2007) 37:2378–89. doi: 10.1002/eji.200737594 [DOI] [PubMed] [Google Scholar]

[B41] 41. Bevington SL, Ng STH, Britton GJ, Keane P, Wraith DC, Cockerill PN. Chromatin priming renders T cell tolerance-associated genes sensitive to activation below the signaling threshold for immune response genes. Cell Rep (2020) 31:107748. doi: 10.1016/j.celrep.2020.107748 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B42] 42. Yadava K, Medina CO, Ishak H, Gurevich I, Kuipers H, Shamskhou EA, et al. Natural tr1-like cells do not confer long-term tolerogenic memory. Elife (2019) 8:e44821. doi: 10.7554/eLife.44821 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B43] 43. Omokanye A, Ong LC, Lebrero-Fernandez C, Bernasconi V, Schön K, Strömberg A, et al. Clonotypic analysis of protective influenza M2e-specific lung resident Th17 memory cells reveals extensive functional diversity. Mucosal Immunol (2022) 15:717–29. doi: 10.1038/s41385-022-00497-9 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B44] 44. Gianfrani C, Levings MK, Sartirana C, Mazzarella G, Barba G, Zanzi D, et al. Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J Immunol (2006) 177:4178–86. doi: 10.4049/jimmunol.177.6.4178 [DOI] [PubMed] [Google Scholar]

[B45] 45. Veldman C, Höhne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol (2004) 172:6468–75. doi: 10.4049/jimmunol.172.10.6468 [DOI] [PubMed] [Google Scholar]

[B46] 46. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med (2012) 209:109–21. doi: 10.1084/jem.20110399 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B47] 47. Kim JE, Sharma A, Sharma G, Lee SY, Shin HS, Rudra D, et al. Lactobacillus pentosus modulates immune response by inducing IL-10 producing Tr1 cells. Immune Netw (2019) 19:e39. doi: 10.4110/in.2019.19.e39 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B48] 48. Maquet C, Baiwir J, Loos P, Rodriguez-Rodriguez L, Javaux J, Sandor R, et al. Ly6Chi monocytes balance regulatory and cytotoxic CD4 T cell responses to control virus-induced immunopathology. Sci Immunol (2022) 7:eabn3240. doi: 10.1126/sciimmunol.abn3240 [DOI] [PubMed] [Google Scholar]

[B49] 49. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood (2010) 116:935–44. doi: 10.1182/blood-2011-08-377416 [DOI] [PubMed] [Google Scholar]

[B50] 50. Mfarrej B, Jofra T, Morsiani C, Gagliani N, Fousteri G, Battaglia M. Key role of macrophages in tolerance induction via T regulatory type 1 (Tr1) cells. Clin Exp Immunol (2020) 201:222–30. doi: 10.1111/cei.13440 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B51] 51. Wakkach A, Cottrez F, Groux H. Differentiation of regulatory T cells 1 is induced by CD2 costimulation. J Immunol (2001) 167:3107–13. doi: 10.4049/jimmunol.167.6.3107 [DOI] [PubMed] [Google Scholar]

[B52] 52. Sutavani RV, Bradley RG, Ramage JM, Jackson AM, Durrant LG, Spendlove I. CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype. J Immunol (2013) 191:5895–903. doi: 10.4049/jimmunol.1301458 [DOI] [PubMed] [Google Scholar]

[B53] 53. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med (2007) 204:105–15. doi: 10.1084/jem.20061660 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B54] 54. Ding Q, Lu L, Wang B, Zhou Y, Jiang Y, Zhou X, et al. B7H1-ig fusion protein activates the CD4 + IFN-γ receptor + type 1 T regulatory subset through IFN-γ-Secreting Th1 cells. J Immunol (2006) 177:3606–14. doi: 10.4049/jimmunol.177.6.3606 [DOI] [PubMed] [Google Scholar]

[B55] 55. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 421:388–92. doi: 10.1038/nature01315 [DOI] [PubMed] [Google Scholar]

[B56] 56. le Friec G, Sheppard D, Whiteman P, Karsten CM, Shamoun SAT, Laing A, et al. The CD46-Jagged1 interaction is critical for human T h 1 immunity. Nat Immunol (2012) 13:1213–21. doi: 10.1038/ni.2454 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B57] 57. Choileain SN, Hay J, Thomas J, Williams A, Vermeren MM, Benezech C, et al. TCR-stimulated changes in cell surface CD46 expression generate type 1 regulatory T cells. Sci Signal (2017) 10:1–13. doi: 10.1126/scisignal.aah6163 [DOI] [PubMed] [Google Scholar]

[B58] 58. Brockmann L, Gagliani N, Steglich B, Giannou AD, Kempski J, Pelczar P, et al. IL-10 receptor signaling is essential for TR1 cell function In vivo . J Immunol (2017) 198:1130–41. doi: 10.4049/jimmunol.1601045 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B59] 59. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo M-G. IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol (2001) 166:5530–9. doi: 10.4049/jimmunol.166.9.5530 [DOI] [PubMed] [Google Scholar]

[B60] 60. Zhang P, Lee JS, Gartlan KH, Schuster IS, Comerford I, Varelias A, et al. Eomesodermin promotes the development of type 1 regulatory T (TR1) cells. Sci Immunol (2017) 2:eaah7152. doi: 10.1126/sciimmunol.aah7152 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B61] 61. Awasthi A, Carrier Y, Peron JPS, Bettelli E, Kamanaka M, Flavell RA, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 8:1380–9. doi: 10.1038/ni1541 [DOI] [PubMed] [Google Scholar]

[B62] 62. Pot C, Jin H, Awasthi A, Liu SM, Lai C-Y, Madan R, et al. Cutting edge: IL-27 induces the transcription factor c-maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-Producing Tr1 cells. J Immunol (2009) 183:797–801. doi: 10.4049/jimmunol.0901233 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B63] 63. Sumida TS, Dulberg S, Schupp JC, Lincoln MR, Stillwell HA, Axisa P, et al. Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat Immunol (2022) 23:632–42. doi: 10.1038/s41590-022-01152-y [DOI] [PMC free article] [PubMed] [Google Scholar]

[B64] 64. Bacchetta R, Gregori S, Serafini G, Sartirana C, Schulz U, Zino E, et al. Molecular and functional characterization of allogantigen specific anergic T cells suitable for cell therapy. Haematologica (2010) 95:2134–43. doi: 10.3324/haematol.2010.025825 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B65] 65. Farez MF, Mascanfroni ID, Méndez-Huergo SP, Yeste A, Murugaiyan G, Garo LP, et al. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell (2015) 162:1338–52. doi: 10.1016/j.cell.2015.08.025 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B66] 66. Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR / Cas9-mediated gene knockout in primary T cells. J Exp Med (2018) 215:985–97. doi: 10.1084/jem.20171626 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B67] 67. Shifrut E, Carnevale J, Tobin V, Roth TL, Woo JM, Bui CT, et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell (2018) 175:1958–1971.e15. doi: 10.1016/j.cell.2018.10.024 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B68] 68. Schmidt R, Steinhart Z, Layeghi M, Freimer JW, Nguyen VQ, Blaeschke F, et al. CRISPR activation and interference screens in primary human T cells decode cytokine regulation. Science (2022) 375:eabj4008. doi: 10.1126/science.abj4008 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B69] 69. Cook L, Stahl M, Han X, Nazli A, MacDonald KN, Wong MQ, et al. Suppressive and gut-reparative functions of human type 1 T regulatory cells. Gastroenterology (2019) 157:1584–98. doi: 10.1053/j.gastro.2019.09.002 [DOI] [PubMed] [Google Scholar]

[B70] 70. Liu JM-H, Chen P, Uyeda MJ, Cieniewicz B, Sayitoglu EC, Thomas BC, et al. Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy. Cytotherapy (2021) 23:10174–1028. doi: 10.1016/j.jcyt.2021.05.010 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B71] 71. Amodio G, Mugione A, Sanchez AM, Viganò P, Candiani M, Somigliana E, et al. HLA-G expressing DC-10 and CD4+ T cells accumulate in human decidua during pregnancy. Hum Immunol (2013) 74:406–11. doi: 10.1016/j.humimm.2012.11.031 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B72] 72. Salvany-Celades M, van der Zwan A, Benner M, Setrajcic-Dragos V, Bougleux Gomes HA, Iyer V, et al. Three types of functional regulatory T cells control T cell responses at the human maternal-fetal interface. Cell Rep (2019) 27:2537–47. doi: 10.1016/j.celrep.2019.04.109 [DOI] [PubMed] [Google Scholar]

[B73] 73. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 75:263–74. doi: 10.1016/0092-8674(93)80068-P [DOI] [PubMed] [Google Scholar]

[B74] 74. Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum (2000) 43:617–27. doi: 10.1002/1529-0131(200003)43:3<617::AID-ANR19>3.0.CO;2-B [DOI] [PubMed] [Google Scholar]

[B75] 75. Wang L, Wang F-S, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med (2015) 278:369–95. doi: 10.1111/joim.12395 [DOI] [PubMed] [Google Scholar]

[B76] 76. Yu H, Gagliani N, Ishigame H, Huber S, Zhu S, Esplugues E, et al. Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development. Proc Natl Acad Sci (2017) 114:10443–8. doi: 10.1073/pnas.1705599114 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B77] 77. Battaglia M, Stabilini A, Draghici E, Migliavacca B, Gregori S, Bonifacio E, et al. Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes (2006) 55:1571–80. doi: 10.2337/db05-1576 [DOI] [PubMed] [Google Scholar]

[B78] 78. Chen C, Lee W-H, Yun P, Snow P, Liu C-P. Induction of autoantigen-specific Th2 and Tr1 regulatory T cells and modulation of autoimmune diabetes. J Immunol (2003) 171:733–44. doi: 10.4049/jimmunol.171.2.733 [DOI] [PubMed] [Google Scholar]

[B79] 79. Prasad S, Neef T, Xu D, Podojil JR, Getts DR, Shea LD, et al. Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells. J Autoimmun (2018) 89:112–24. doi: 10.1016/j.jaut.2017.12.010 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B80] 80. Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature (2016) 530:434–40. doi: 10.1038/nature16962 [DOI] [PubMed] [Google Scholar]

[B81] 81. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest (2004) 113:451–63. doi: 10.1172/JCI19585 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B82] 82. Petrich de Marquesini LG, Fu J, Connor KJ, Bishop AJ, McLintock NE, Pope C, et al. IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia (2010) 53:1451–60. doi: 10.1007/s00125-010-1739-3 [DOI] [PubMed] [Google Scholar]

[B83] 83. Sanda S, Roep BO, von Herrath M. Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. Clin Immunol (2008) 127:138–43. doi: 10.1016/j.clim.2007.12.003 [DOI] [PubMed] [Google Scholar]

[B84] 84. Chujo D, Nguyen T-S, Foucat E, Blankenship D, Banchereau J, Nepom GT, et al. Adult-onset type 1 diabetes patients display decreased IGRP-specific Tr1 cells in blood. Clin Immunol (2015) 161:270–7. doi: 10.1016/j.clim.2015.08.014 [DOI] [PubMed] [Google Scholar]

[B85] 85. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-ala). J Clin Invest (2003) 111:409–18. doi: 10.1172/JCI16090 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B86] 86. Alhadj Ali M, Liu Y-F, Arif S, Tatovic D, Shariff H, Gibson VB, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med (2017) 9:eaaf7779. doi: 10.1126/scitranslmed.aaf7779 [DOI] [PubMed] [Google Scholar]

[B87] 87. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, et al. In vitro generation of interleukin 10–producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)– and Th2-inducing cytokines. J Exp Med (2002) 195:603–16. doi: 10.1084/jem.20011629 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B88] 88. Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol (2013) 14:1054–63. doi: 10.1038/ni.2695 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B89] 89. Raverdeau M, Christofi M, Malara A, Wilk MM, Misiak A, Kuffova L, et al. Retinoic acid-induced autoantigen-specific type 1 regulatory T cells suppress autoimmunity. EMBO Rep (2019) 20:e47121. doi: 10.15252/embr.201847121 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B90] 90. Kenison JE, Jhaveri A, Li Z, Khadse N, Tjon E, Tezza S, et al. Tolerogenic nanoparticles suppress central nervous system inflammation. Proc Natl Acad Sci (2020) 117:32017–28. doi: 10.1073/pnas.2016451117 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B91] 91. Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest (2006) 116:3252–7. doi: 10.1172/JCI29251 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B92] 92. Caielli S, Veiga DT, Balasubramanian P, Athale S, Domic B, Murat E, et al. A CD4+ T cell population expanded in lupus blood provides b cell help through interleukin-10 and succinate. Nat Med (2019) 25:75–81. doi: 10.1038/s41591-018-0254-9 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B93] 93. Asnagli H, Martire D, Belmonte N, Quentin J, Bastian H, Boucard-Jourdin M, et al. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Arthritis Res Ther (2014) 16:R115. doi: 10.1186/ar4567 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B94] 94. Kim J, Lee J, Gonzalez J, Fuentes-Duculan J, Garcet S, Krueger JG. Proportion of CD4+CD49b+LAG-3+ type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index. J Invest Dermatol (2018) 138:2669–72. doi: 10.1016/j.jid.2018.05.021 [DOI] [PubMed] [Google Scholar]

[B95] 95. Kelly CP, Murray JA, Leffler DA, Getts DR, Bledsoe AC, Smithson G, et al. TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: A randomized, double-blind, placebo-controlled study. Gastroenterology (2021) 161:66–80.e8. doi: 10.1053/j.gastro.2021.03.014 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B96] 96. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med (1999) 190:995–1004. doi: 10.1084/jem.190.7.995 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B97] 97. Huber S, Gagliani N, Esplugues E, O’Connor W, Huber FJ, Chaudhry A, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3– and Foxp3+ regulatory CD4+ T cells in an interleukin-10-Dependent manner. Immunity (2011) 34:554–65. doi: 10.1016/j.immuni.2011.01.020 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B98] 98. Doñas C, Neira J, Osorio-Barrios F, Carrasco M, Fernández D, Prado C, et al. The demethylase inhibitor GSK-J4 limits inflammatory colitis by promoting de novo synthesis of retinoic acid in dendritic cells. Sci Rep (2021) 11:1342. doi: 10.1038/s41598-020-79122-3 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B99] 99. Qi L, Wu J, Zhu S, Wang X, Lv X, Liu C, et al. Mesenchymal stem cells alleviate inflammatory bowel disease Via Tr1 cells. Stem Cell Rev Rep (2022) 18:2444–57. doi: 10.1007/s12015-022-10353-9 [DOI] [PubMed] [Google Scholar]

[B100] 100. Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory crohn’s disease. Gastroenterology (2012) 143:1207–1217.e2. doi: 10.1053/j.gastro.2012.07.116 [DOI] [PubMed] [Google Scholar]

[B101] 101. Chatenoud L, Ferran C, Bach J-F. The anti-CD3-Induced syndrome: A consequence of massive In vivo cell activation. In: Fleischer B, Sjögren HO (eds) Superantigens. Current Topics in Microbiology and Immunology. (Berlin, Heidelberg: Springer) 174. (1991), 121–34. doi: 10.1007/978-3-642-50998-8_9 [DOI] [PubMed] [Google Scholar]

[B102] 102. Jamison BL, Neef T, Goodspeed A, Bradley B, Baker RL, Miller SD, et al. Nanoparticles containing an insulin–ChgA hybrid peptide protect from transfer of autoimmune diabetes by shifting the balance between effector T cells and regulatory T cells. J Immunol (2019) 203:48–57. doi: 10.4049/jimmunol.1900127 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B103] 103. Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol (2012) 30:1217–24. doi: 10.1038/nbt.2434 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B104] 104. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol (2020) 5:17–30. doi: 10.1016/S2468-1253(19)30333-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B105] 105. Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, et al. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol (2006) 177:5852–60. doi: 10.4049/jimmunol.177.9.5852 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B106] 106. Kamanaka M, Kim ST, Wan YY, Sutterwala FS, Lara-Tejero M, Galán JE, et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity (2006) 25:941–52. doi: 10.1016/j.immuni.2006.09.013 [DOI] [PubMed] [Google Scholar]

[B107] 107. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3– precursor cells in the absence of interleukin 10. Nat Immunol (2007) 8:931–41. doi: 10.1038/ni1504 [DOI] [PubMed] [Google Scholar]

[B108] 108. Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK. Regulatory T-cell therapy for inflammatory bowel disease: More questions than answers. Immunology (2012) 136:115–22. doi: 10.1111/j.1365-2567.2012.03572.x [DOI] [PMC free article] [PubMed] [Google Scholar]

[B109] 109. Asseman C, Read S, Powrie F. Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: Control by CD4 ⁺ regulatory T cells and IL-10. J Immunol (2003) 171:971–8. doi: 10.4049/jimmunol.171.2.971 [DOI] [PubMed] [Google Scholar]

[B110] 110. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity (2008) 28:546–58. doi: 10.1016/j.immuni.2008.02.017 [DOI] [PubMed] [Google Scholar]

[B111] 111. Roers A, Siewe L, Strittmatter E, Deckert M, Schlüter D, Stenzel W, et al. T Cell–specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med (2004) 200:1289–97. doi: 10.1084/jem.20041789 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B112] 112. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich J-M, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity (2011) 34:566–78. doi: 10.1016/j.immuni.2011.03.018 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B113] 113. McGuirk P, McCann C, Mills KHG. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: A novel strategy for evasion of protective T helper type 1 responses by bordetella pertussis. J Exp Med (2002) 195:221–31. doi: 10.1084/jem.20011288 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B114] 114. Jofra T, di Fonte R, Galvani G, Kuka M, Iannacone M, Battaglia M, et al. Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection. Eur J Immunol (2018) 48:1389–99. doi: 10.1002/eji.201747316 [DOI] [PubMed] [Google Scholar]

[B115] 115. Eliasson DG, Omokanye A, Schön K, Wenzel UA, Bernasconi V, Bemark M, et al. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection. Mucosal Immunol (2018) 11:273–89. doi: 10.1038/mi.2017.14 [DOI] [PubMed] [Google Scholar]

[B116] 116. Antunes I, Kassiotis G. Suppression of innate immune pathology by regulatory T cells during influenza a virus infection of immunodeficient mice. J Virol (2010) 84:12564–75. doi: 10.1128/jvi.01559-10 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B117] 117. Brincks EL, Roberts AD, Cookenham T, Kohlmeier JE, Blackman MA, David L. Antigen-specific memory regulatory CD4 + Foxp3 + T cells control memory responses to influenza virus infection. J Immunol (2013) 190:3438–46. doi: 10.4049/jimmunol.1203140 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B118] 118. Moser EK, Hufford MM, Braciale TJ. Late engagement of CD86 after influenza virus clearance promotes recovery in a FoxP3 + regulatory T cell dependent manner. PloS Pathog (2014) 10:e1004315. doi: 10.1371/journal.ppat.1004315 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B119] 119. Rogers MC, Lamens KD, Shafagati N, Johnson M, Oury TD, Joyce S, et al. CD4 + regulatory T cells exert differential functions during early and late stages of the immune response to respiratory viruses. J Immunol (2018) 201:1253–66. doi: 10.4049/jimmunol.1800096 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B120] 120. Lu C, Zanker D, Lock P, Jiang X, Deng J, Duan M, et al. Memory regulatory T cells home to the lung and control influenza a virus infection. Immunol Cell Biol (2019) 97:774–86. doi: 10.1111/imcb.12271 [DOI] [PubMed] [Google Scholar]

[B121] 121. Doetze A, Satoguina J, Burchard G, Rau T, Loliger C, Fleischer B, et al. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. Int Immunol (2000) 12:623–30. [DOI] [PubMed] [Google Scholar]

[B122] 122. Koch K, Koch N, Sandaradura De Silva U, Jung N, Schulze Zur Wiesch J, Fatkenheuer G, et al. Increased frequency of CD49b/LAG-3+ type 1 regulatory T cells in HIV-infected individuals. AIDS Res Hum Retroviruses (2015) 31:1238–46. doi: 10.1089/aid.2014.0356 [DOI] [PubMed] [Google Scholar]

[B123] 123. Moreira Genaro L, de Oliveira Coser L, da Silva Justo Junior A, Furquim de Castro L, Felício Barreto AK, Rizzato AE, et al. Association between IL-27 and Tr1 cells in severe form of paracoccidioidomycosis. Cytokine (2020) 127:154962. doi: 10.1016/j.cyto.2019.154962 [DOI] [PubMed] [Google Scholar]

[B124] 124. MacDonald AJ, Duffy M, Brady MT, McKiernan S, Hall W, Hegarty J, et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis c virus-infected persons. J Infect Dis (2002) 185:720–7. doi: 10.1086/339340 [DOI] [PubMed] [Google Scholar]

[B125] 125. Brady MT, MacDonald AJ, Rowan AG, Mills KHG. Hepatitis c virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol (2003) 33:3448–57. doi: 10.1002/eji.200324251 [DOI] [PubMed] [Google Scholar]

[B126] 126. Carpentier A, Conti F, Stenard F, Aoudjehane L, Miroux C, Podevin P, et al. Increased expression of regulatory Tr1 cells in recurrent hepatitis c after liver transplantation. Am J Transplant (2009) 9:2102–12. doi: 10.1111/j.1600-6143.2009.02743.x [DOI] [PubMed] [Google Scholar]

[B127] 127. Fabien S, Olivier M, Khaldoun G, Vivian V, Lynda A, Laurissa O, et al. CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis c after liver transplantation. BioMed Res Int (2014) 2014:290878. doi: 10.1155/2014/290878 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B128] 128. Utsumi M, Takaki A, Umeda Y, Koike K, Napier SC, Watanabe N, et al. Frequency of regulatory T-cell and hepatitis c viral antigen-specific immune response in recurrent hepatitis c after liver transplantation. Transpl Immunol (2014) 31:33–41. doi: 10.1016/j.trim.2014.05.006 [DOI] [PubMed] [Google Scholar]

[B129] 129. Ghazal K, Morales O, Barjon C, Dahlqvist G, Aoudjehane L, Ouaguia L, et al. Early high levels of regulatory T cells and T helper 1 may predict the progression of recurrent hepatitis c after liver transplantation. Clin Res Hepatol Gastroenterol (2019) 43:273–81. doi: 10.1016/j.clinre.2018.10.005 [DOI] [PubMed] [Google Scholar]

[B130] 130. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: More questions than answers. Nat Immunol (2008) 9:725–32. doi: 10.1038/ni.f.205 [DOI] [PubMed] [Google Scholar]

[B131] 131. Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, Kamya MR, Rosenthal PJ, Rek J, et al. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure. Elife (2018) 7:e35832. doi: 10.7554/eLife.35832 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B132] 132. Jagannathan P, Eccles-James I, Bowen K, Nankya F, Auma A, Wamala S, et al. IFNγ/IL-10 Co-producing cells dominate the CD4 response to malaria in highly exposed children. PloS Pathog (2014) 10:e1003864. doi: 10.1371/journal.ppat.1003864 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B133] 133. Freitas do Rosário AP, Lamb T, Spence P, Stephens R, Lang A, Roers A, et al. IL-27 promotes IL-10 production by effector Th1 CD4 + T cells: A critical mechanism for protection from severe immunopathology during malaria infection. J Immunol (2012) 188:1178–90. doi: 10.4049/jimmunol.1102755 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B134] 134. Loevenich K, Ueffing K, Abel S, Hose M, Matuschewski K, Westendorf AM, et al. DC-Derived IL-10 modulates pro-inflammatory cytokine production and promotes induction of CD4+IL-10+ regulatory T cells during plasmodium yoelii infection. Front Immunol (2017) 8:152. doi: 10.3389/fimmu.2017.00152 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B135] 135. Abel S, Lückheide N, Westendorf AM, Geffers R, Roers A, Müller W, et al. Strong impact of CD4+ Foxp3+ regulatory T cells and limited effect of T cell-derived IL-10 on pathogen clearance during plasmodium yoelii infection. J Immunol (2012) 188:5467–77. doi: 10.4049/jimmunol.1102223 [DOI] [PubMed] [Google Scholar]

[B136] 136. Couper KN, Blount DG, Wilson MS, Hafalla JC, Belkaid Y, Kamanaka M, et al. IL-10 from CD4+CD25-Foxp3-CD127 - adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection. PloS Pathog (2008) 4:e1000004. doi: 10.1371/journal.ppat.1000004 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B137] 137. Lönnberg T, Svensson V, James KR, Fernandez-Ruiz D, Sebina I, Montandon R, et al. Single-cell RNA-seq and computational analysis using temporal mixture modeling resolves TH1/TFH fate bifurcation in malaria. Sci Immunol (2017) 2:eaal2192. doi: 10.1126/sciimmunol.aal2192 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B138] 138. Soon MSF, Lee HJ, Engel JA, Straube J, Thomas BS, Pernold CPS, et al. Transcriptome dynamics of CD4+ T cells during malaria maps gradual transit from effector to memory. Nat Immunol (2020) 21:1597–610. doi: 10.1038/s41590-020-0800-8 [DOI] [PubMed] [Google Scholar]

[B139] 139. Neumann C, Scheffold A, Rutz S. Functions and regulation of T cell-derived interleukin-10. Semin Immunol (2019) 44:101344. doi: 10.1016/j.smim.2019.101344 [DOI] [PubMed] [Google Scholar]

[B140] 140. Boyle MJ, Jagannathan P, Bowen K, McIntyre TI, Vance HM, Farrington LA, et al. The development of plasmodium falciparum-specific IL10 CD4 T cells and protection from malaria in children in an area of high malaria transmission. Front Immunol (2017) 8:1329. doi: 10.3389/fimmu.2017.01329 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B141] 141. Mackroth MS, Abel A, Steeg C, Schulze zur Wiesch J, Jacobs T. Acute malaria induces PD1+CTLA4+ effector T cells with cell-extrinsic suppressor function. PloS Pathog (2016) 12:1–24. doi: 10.1371/journal.ppat.1005909 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B142] 142. Brandi J, Lehmann C, Kaminski LC, Schulze zur Wiesch J, Addo M, Ramharter M, et al. T Cells expressing multiple co-inhibitory molecules in acute malaria are not exhausted but exert a suppressive function in mice. Eur J Immunol (2022) 52:312–27. doi: 10.1002/eji.202149424 [DOI] [PubMed] [Google Scholar]

[B143] 143. Brandi J, Riehn M, Hadjilaou A, Jacobs T. Increased expression of multiple Co-inhibitory molecules on malaria-induced CD8+ T cells are associated with increased function instead of exhaustion. Front Immunol (2022) 13:878320. doi: 10.3389/fimmu.2022.878320 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B144] 144. Christoffersson G, von Herrath M. Regulatory immune mechanisms beyond regulatory T cells. Trends Immunol (2019) 40:482–91. doi: 10.1016/j.it.2019.04.005 [DOI] [PubMed] [Google Scholar]

[B145] 145. Passerini L, di Nunzio S, Gregori S, Gambineri E, Cecconi M, Seidel MG, et al. Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur J Immunol (2011) 41:1120–31. doi: 10.1002/eji.201040909 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B146] 146. Narula M, Lakshmanan U, Borna S, Schulze JJ, Holmes TH, Harre N, et al. Epigenetic and immunological indicators of IPEX disease in subjects with FOXP3 gene mutation. J Allergy Clin Immunol (2022). doi: 10.1016/j.jaci.2022.09.013 [DOI] [PubMed] [Google Scholar]

[B147] 147. Lio CWJ, Hsieh CS. Becoming self-aware: The thymic education of regulatory T cells. Curr Opin Immunol (2011) 23:213–9. doi: 10.1016/j.coi.2010.11.010 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B148] 148. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med (2004) 199:1567–75. doi: 10.1084/jem.20032058 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B149] 149. Pacciani V, Gregori S, Chini L, Corrente S, Chianca M, Moschese V, et al. Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites. J Allergy Clin Immunol (2010) 125:727–36. doi: 10.1016/j.jaci.2009.12.004 [DOI] [PubMed] [Google Scholar]

[B150] 150. Pellerin L, Jenks JA, Chinthrajah S, Dominguez T, Block W, Zhou X, et al. Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired. J Allergy Clin Immunol (2018) 141:202–213.e8. doi: 10.1016/j.jaci.2017.05.045 [DOI] [PubMed] [Google Scholar]

[B151] 151. Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer J-P, Groux H. A comparative study between T regulatory type 1 and CD4+CD25+ T cells in the control of inflammation. J Immunol (2003) 171:5018–26. doi: 10.4049/jimmunol.171.10.5018 [DOI] [PubMed] [Google Scholar]

[B152] 152. Feunou P, Poulin L, Habran C, le Moine A, Goldman M, Braun MY. CD4+ CD25+ and CD4+ CD25– T cells act respectively as inducer and effector T suppressor cells in superantigen-induced tolerance. J Immunol (2003) 171:3475–84. doi: 10.4049/jimmunol.171.7.3475 [DOI] [PubMed] [Google Scholar]

[B153] 153. Grundström S, Cederbom L, Sundstedt A, Scheipers P, Ivars F. Superantigen-induced regulatory T cells display different suppressive functions in the presence or absence of natural CD4+ CD25+ regulatory T cells In vivo . J Immunol (2003) 170:5008–17. doi: 10.4049/jimmunol.170.10.5008 [DOI] [PubMed] [Google Scholar]

PERMALINK

Erratum: Type 1 regulatory T cell-mediated tolerance in health and disease

Table 1.

References

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

Erratum: Type 1 regulatory T cell-mediated tolerance in health and disease

Table 1.

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases